CCL5 and cancer: When the cells were treated with a combination of cetuximab and MEK or JNK, the expression levels of CCL5, CXCL9 and CXCL10 increased, confirming that not one but multiple pathways downstream of the EGFR act in concert to block IFNγ/TNFα -induced chemokine expression by these cancer cell lines.